Cognitive Enhancer Nootropic White Powder Sunifiram As Effective Anti-Amnesiac Drug For Brain Nootropics

Cognitive Enhancer Nootropic White Powder Sunifiram As Effective Anti-Amnesiac Drug For Brain Nootropics

Detalle rápido

Nombre del producto: Sunifiram

CASO: 314728-85-3

Apariencia: polvo blanco

pureza: 99%

Marca comercial: Pharmlab

Original: porcelana

Calificación: Grado farmacéutico

Paquete: Paquete disfrazado ; Bolsa de aluminio

Fecha de entrega: 3-5 dias laborables

Certificado: YO ASI 9001, USP,GMP

Pago: Western Union, MoneyGram, T / T, bitcoin

Transporte: EMS,HKEMS,EUB,EFECTO,FEDEX,DHL,UPS,Aramex,ETC

Política: Política de reenvío

MW: 246.31176

Store at:Room temperature

Abstracto

Sunifiram is one of the newest nootropics on the market to smart drugs family. It is considered to be in the ampakine family of supplements. It increases one’s attention span, Toma de decisiones, and learning abilities. Although it is believed to work much like Piracetam, it is highly potent in comparison. The structure is similar, but some have reported Sunifiram being 1000 times more potent. In terms of its potency, it’s comparable to Noopept.

It is being researched as a memory enhancer, potentially treating Alzheimer’s patients. It provides a wide variety of benefits including; increased attention span, improved focus, and increased learning potential. It has become very popular since its release, as the benefits are high and the side-effects are low.

Descripción

Sunifiram (DM-235) is a synthetic derivative of Piracetam, although due to breaking the pyrrolidone backbone it is no longer in the Racetam class of drugs (yet by being derived from them, it is still commonly associated with this class).
Sunifiram has mechanisms similar to Nefiracetam in the hippocampus, and similar to that drug sunifiram shows anti-amnesiac properties and is potentially a cognitive enhancer. Its anti-amnesiac activity is several orders of magnitude greater than piracetam on a per weight basis, and preliminary evidence suggest it has a similarly low toxicity profile.

This compound is known as an AMPAkine due to exerting most of its actions via the AMPA receptor (one of the three main subsets of glutamate receptors, alongside NDMA and kainate). This enhancement of AMPA function seems to also rely on enhancing signalling via the Glycine binding site of NMDA receptors, although one minimal signalling goes through the NMDA receptor then the benefits on AMPA receptors seem dose-dependent.